Trial Profile
A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Encequidar+paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Athenex
- 15 Feb 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 10 Aug 2021 Planned End Date changed from 1 Jul 2021 to 31 Dec 2021.
- 16 Mar 2021 Planned End Date changed from 31 Mar 2021 to 1 Jul 2021.